Toshiyuki Kawai

Dr. Toshiyuki Kawai

Department of Orthopaedic Surgery, Kyoto University, Kyoto 606-8501, Japan
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2010 in Journal of The Royal Society Interface
Verified
Journal Article
Closed access
PDF file
TKTadashi Kokubo
Tadashi Kokubo
DPDeepak K. Pattanayak
Deepak K. Pattanayak
SYSeiji Yamaguchi
Seiji Yamaguchi
HTHiroaki Takadama
Hiroaki Takadama
TMTomiharu Matsushita
Tomiharu Matsushita
TNTakashi Nakamura
Takashi Nakamura
A highly bioactive bone-bonding Ti metal was obtained when Ti metal was simply heat-treated after a common acid treatment. This bone-bonding property was ascribed to the formation of apatite on the Ti metal in a body environment. The formation of apatite on the Ti metal was induced neither by its surface roughness nor by the rutile phase precipitated on its surface, but by its positively charged surface. The surface of the Ti metal was positively charged because acid groups were adsorbed on titanium hydride formed on the Ti metal by the acid treatment, and remained even after the titanium hydride was transformed into titanium oxide by the subsequent heat treatment. These results provide a new principle based on a positively charged surface for obtaining bioactive materials.

1 October 2019 in Bone & Joint Research
Verified
Journal Article
Open access
YKYutaka Kuroda
Yutaka Kuroda
TTTakeyuki Tanaka
Takeyuki Tanaka
TMTakaki Miyagawa
Takaki Miyagawa
Toshiyuki KawaiToshiyuki Kawai
Toshiyuki Kawai
KGKoji Goto
Koji Goto
HAHaruhiko Akiyama
Haruhiko Akiyama
Objectives: Using a simple classification method, we aimed to estimate the collapse rate due to osteonecrosis of the femoral head (ONFH) in order to develop treatment guidelines for joint-preserving surgeries. Methods: We retrospectively analyzed 505 hips from 310 patients (141 men, 169 women; mean age 45.5 years (sd 14.9; 15 to 86)) diagnosed with ONFH and classified them using the Japanese Investigation Committee (JIC) classification. The JIC system includes four visualized types based on the location and size of osteonecrotic lesions on weightbearing surfaces (types A, B, C1, and C2) and the stage of ONFH. The collapse rate due to ONFH was calculated using Kaplan–Meier survival analysis, with radiological collapse/arthroplasty as endpoints. Results: Bilateral cases accounted for 390 hips, while unilateral cases accounted for 115. According to the JIC types, 21 hips were type A, 34 were type B, 173 were type C1, and 277 were type C2. At initial diagnosis, 238/505 hips (47.0%) had already collapsed. Further, the cumulative survival rate was analyzed in 212 precollapsed hips, and the two-year and five-year collapse rates were found to be 0% and 0%, 7.9% and 7.9%, 23.2% and 36.6%, and 57.8% and 84.8% for types A, B, C1, and C2, respectively. Conclusion: Type A ONFH needs no further treatment, but precollapse type C2 ONFH warrants immediate treatment with joint-preserving surgery. Considering the high collapse rate, our study results justify the importance of early diagnosis and intervention in asymptomatic patients with type C2 ONFH. Cite this article: Y. Kuroda, T. Tanaka, T. Miyagawa, T. Kawai, K. Goto, S. Tanaka, S. Matsuda, H. Akiyama. Classification of osteonecrosis of the femoral head: Who should have surgery?. Bone Joint Res 2019;8:451–458. DOI: 10.1302/2046-3758.810.BJR-2019-0022.R1.

1 December 2018 in Biomaterials
Verified
Journal Article
Closed access
MMMasahiro Maruyama
Masahiro Maruyama
ANAkira Nabeshima
Akira Nabeshima
CPChi-Chun Pan
Chi-Chun Pan
ABAnthony W. Behn
Anthony W. Behn
TTTimothy Thio
Timothy Thio
YYYunzhi Peter Yang
Yunzhi Peter Yang

1 July 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
YOYu Okae
Yu Okae
KNKohei Nishitani
Kohei Nishitani
ASAkio Sakamoto
Akio Sakamoto
Toshiyuki KawaiToshiyuki Kawai
Toshiyuki Kawai
TTTakuya Tomizawa
Takuya Tomizawa
SMShuichi Matsuda
Shuichi Matsuda
The formation of a biofilm on the implant surface is a major cause of intractable implant-associated infection. To investigate the antibiotic concentration needed to eradicate the bacteria inside a biofilm, the minimum biofilm eradication concentration (MBEC) has been used, mostly against in vitro biofilms on plastic surfaces. To produce a more clinically relevant environment, an MBEC assay against biofilms on stainless-steel implants formed in a rat femoral infection model was developed. The rats were implanted with stainless steel screws contaminated by two Staphylococcus aureus strains (UAMS-1, methicillin-sensitive Staphylococcus aureus; USA300LAC, methicillin-resistant Staphylococcus aureus) and euthanized on days 3 and 14. Implants were harvested, washed, and incubated with various concentrations (64–4096 μg/mL) of gentamicin (GM), vancomycin (VA), or cefazolin (CZ) with or without an accompanying systemic treatment dose of VA (20 μg/mL) or rifampicin (RF) (1.5 μg/mL) for 24 h. The implant was vortexed and sonicated, the biofilm was removed, and the implant was re-incubated to determine bacterial recovery. MBEC on the removed biofilm and implant was defined as in vivo MBEC and in vivo implant MBEC, respectively, and the concentrations of 100% and 60% eradication were defined as MBEC100 and MBEC60, respectively. As for in vivo MBEC, MBEC100 of GM was 256–1024 μg/mL, but that of VA and CZ ranged from 2048–4096 μg/mL. Surprisingly, the in vivo implant MBEC was much higher, ranging from 2048 μg/mL to more than 4096 μg/mL. The addition of RF, not VA, as a secondary antibiotic was effective, and MBEC60 on day 3 USA300LAC biofilm was reduced from 1024 μg/mL with GM alone to 128 μg/mL in combination with RF and the MBEC60 on day 14 USA300LAC biofilm was reduced from 2048 μg/mL in GM alone to 256 μg/mL in combination with RF. In conclusion, a novel MBEC assay for in vivo biofilms on orthopedic implants was developed. GM was the most effective against both methicillin-sensitive and methicillin-resistant Staphylococcus aureus, in in vivo biofilms, and the addition of a systemic concentration of RF reduced MBEC of GM. Early initiation of treatment is desired because the required concentration of antibiotics increases with biofilm maturation.

21 August 2017 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
PDF file
Toshiyuki KawaiToshiyuki Kawai
Toshiyuki Kawai
YSYaser Shanjani
Yaser Shanjani
SFSaba Fazeli
Saba Fazeli
ABAnthony W. Behn
Anthony W. Behn
YOYaichiro Okuzu
Yaichiro Okuzu
YYYunzhi Peter Yang
Yunzhi Peter Yang

29 March 2015 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
MTMitsuru Takemoto
Mitsuru Takemoto
SFShunsuke Fujibayashi
Shunsuke Fujibayashi
EOEigo Ota
Eigo Ota
BOBungo Otsuki
Bungo Otsuki
HKHiroaki Kimura
Hiroaki Kimura
SMShuich Matsuda
Shuich Matsuda